(Q42054203)

15 October 2017

1 reference

title

Fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies (English)

1 reference

15 October 2017

Post JB 4th

1

1 reference

15 October 2017

Frishman WH

series ordinal

2

1 reference

15 October 2017

language of work or name

1 reference

1 January 1998

1 reference

The Journal of Clinical Pharmacology

15 October 2017

published in

1 reference

15 October 2017

volume

38

1 reference

15 October 2017

issue

1

1 reference

15 October 2017

page(s)

2-13

1 reference

Management of hypertensive urgencies and emergencies

15 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Role of dopaminergic mechanisms in the kidney for the pathogenesis of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Defective dopamine-1 receptor adenylate cyclase coupling in the proximal convoluted tubule from the spontaneously hypertensive rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Cardiovascular pharmacology of adrenergic and dopaminergic receptors: therapeutic significance in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Hemodynamic, renal, and neurohumoral effects of a selective oral DA1 receptor agonist (fenoldopam) in patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

The DA1 receptor agonist fenoldopam (SK & F 82526) is also an alpha 2-adrenoceptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Effect of concomitant food intake on absorption kinetics of fenoldopam (SK&F 82526) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Continuous intragastric delivery of fenoldopam: relationship between plasma concentration and effects on renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

A comparison of fenoldopam and nitroprusside in the control of hypertension following coronary artery surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Interaction study of fenoldopam--digoxin in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

Selective and nonselective dopamine receptor agonists: an innovative approach to cardiovascular disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04369.X

10.1002/J.1552-4604.1998.TB04369.X

21 January 2018

Identifiers

DOI

1 reference

15 October 2017

1 reference